Clinical trials: Recurrent or Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma
A prospective, single-arm,mutil-center study to assess the efficacy and safety of Surufatinib combined with Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.
- Trial name
- NCT04955886
- Testing
- Surufatinib(HMPL-012)
- Where
- 2 sites in China
- Volunteers
- 14 people
- Sponsor
- Fujian Cancer Hospital
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
This phase II trial studies how well lapatinib ditosylate works in treating patients with metastatic or recurrent head and neck cancer.
- Conditions
- Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT00114283
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
NPC, HNSCC
A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
Phase II: To evaluate the safety and tolerability of IAE0972 combined with chemotherapy selected by doctors for R/M HNSCC/NPC after failure or progress of ≤2-line system therapy, and to determine the MTD of combined therapy.
- Conditions
- NPC, HNSCC, Recurrence, Metastasis
- Trial name
- NCT06719479
- Testing
- IAE0972+ Methotrexate, IAE0972+Docetaxel, IAE0972+Gemcitabine
- Volunteers
- 60 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00939627
- Testing
- cetuximab, sorafenib tosylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
This phase I/II trial studies the side effects and the best dose of sorafenib tosylate and docetaxel when given together with cisplatin and to see how well they work in treating patients with recurrent or metastatic squamous cell…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT02035527
- Testing
- sorafenib tosylate, cisplatin, docetaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Nasopharyngeal Carcinoma by AJCC V8 Stage
Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC
A Randomized, Double-Blind, Multi-Center Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody Injection) + Serplulimab (HLX10, Recombinant Anti-PD-1 Humanized…
- Trial name
- NCT05513573
- Testing
- HLX07, HLX10, chemotherapy
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Shanghai Henlius Biotech
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
This randomized phase I/II trial studies the side effects, best way to give, and best dose of erlotinib and bevacizumab when given with cetuximab and how well giving erlotinib and cetuximab together with or without bevacizumab…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer
- Trial name
- NCT00101348
- Testing
- erlotinib hydrochloride, cetuximab, bevacizumab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- DORA (NCT01313390)
- Testing
- docetaxel, everolimus, laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- University College, London
Nasopharyngeal Carcinoma (NPC)
Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
This study is designed as a single-arm, open-label, phase II trial to evaluate the efficacy and safety of ivonescimab in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have progressed on prior an immune…
- Trial name
- AK112 (NCT07565389)
- Testing
- Ivonescimab 20 mg/kg
- Where
- Singapore
- Volunteers
- 42 people
- Sponsor
- National University Hospital, Singapore
Head and Neck Cancer
Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00448552
- Testing
- capecitabine, oxaliplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Miami
Nasopharyngeal Carcinoma
A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
- Trial name
- NCT02878889
- Testing
- S-1
- Where
- 2 sites in China
- Volunteers
- 53 people
- Sponsor
- Zhejiang Cancer Hospital
Head and Neck Cancer
Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01192750
- Testing
- immunohistochemistry staining method, laboratory biomarker analysis, medical chart review
- Volunteers
- 79 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Colorectal Cancer, Head and Neck Cancer
Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases
RATIONALE: Diagnostic procedures using boronophenylalanine-fructose complex (BPA-F) and/or sodium borocaptate (BSH) to detect the presence of boron in tumor cells may help determine whether patients who have thyroid cancer, head…
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Metastatic Cancer
- Trial name
- NCT00062348
- Testing
- boronophenylalanine-fructose complex, sodium borocaptate, conventional surgery
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Cancer
AP5346 or Oxaliplatin in Treating Patients With Metastatic and/or Unresectable Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as AP5346 and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00415298
- Testing
- DACH polymer platinate AP5346, oxaliplatin, gene expression analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Diego
Head and Neck Cancer
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
Participant with squamous cell cancer of head and neck are invited to participate in this study. In this study the investigators will be Inserting the gene for interleukin-12 into a person's cancer cells with the anticipation to…
- Trial name
- NCT00004070
- Testing
- IL-12
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Cancer
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00040807
- Testing
- docetaxel, irinotecan hydrochloride
- Where
- 43 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Colorectal Cancer, Endometrial Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more effective treatment for solid tumors.
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00019331
- Testing
- aldesleukin, ras peptide cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Locally Recurrent Cancer, Metastatic Nasopharyngeal Cancer
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
This is a single center, randomized, phase Ib/II open-label study of pembrolizumab (pembro or MK-3475) with or without bevacizumab in patients with recurrent non-curable or metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- 2018/00947 (NCT03813394)
- Testing
- pembrolizumab, bevacizumab
- Where
- Singapore
- Volunteers
- 48 people
- Sponsor
- National University Hospital, Singapore
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck
This phase I trial studies the side effects and best dose of TLR8 Agonist VTX-2337 when given together with cetuximab in treating patients with locally advanced, recurrent, or metastatic squamous cell cancer of the head and neck…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01334177
- Testing
- TLR8 agonist VTX-2337, cetuximab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Washington
Recurrent or Metastatic NPC
The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer
This is a randomized, placebo-controlled, multi-center, double blinded, Phase III study to determine the efficacy and safety of TORIPALIMAB INJECTIO（JS001） in combination with gemcitabine/cisplatin compared with placebo in…
- Trial name
- NCT03581786
- Testing
- TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy
- Where
- 32 sites in China, Singapore and 1 more
- Volunteers
- 289 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.